Results 261 to 270 of about 995,700 (356)
This review highlights recent progress in nanocarriers targeting pattern recognition receptors (PRRs), including Toll‐like and NOD‐like receptors, for enhancing the treatment of bacterial sepsis and related complications. These nanomedicines deliver antibiotics and anti‐inflammatory agents while modulating immune responses.
Eman A. Ismail+3 more
wiley +1 more source
Sendai-viral HN and F glycoproteins as probes of plasma-membrane protein catabolism in HTC cells. Studies with fusogenic reconstituted Sendai-viral envelopes [PDF]
Rupert Earl+3 more
openalex +1 more source
Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision
Advancements in ART improve HIV‐1 patient outcomes but are unable to eliminate latent viral DNA. To address this, CXCR4‐targeted lipid nanoparticles (T‐LNPs) for delivering CRISPR‐Cas9 to excise HIV‐1 DNA in infected cells are developed. These T‐LNPs achieve ≈60% HIV‐1 DNA excision efficacy in blood and splenic tissue, demonstrating promise for ...
Sudipta Panja+6 more
wiley +1 more source
Viral proteins resolve the virus-vector conundrum during hemipteran-mediated transmission by subverting salicylic acid signaling pathway. [PDF]
Zhang JR+8 more
europepmc +1 more source
Inhibitors of protein glycosylation and glycoprotein processing in viral systems
R. Datema+2 more
openalex +1 more source
Extracellular vesicles (EVs) are pivotal mediators of intercellular communication and disease, yet the fundamental mechanisms controlling their biogenesis and cargo selection remain unclear. This limitation hinders their diagnostic utility and therapeutic development.
Luís Carvalho Ferraz+2 more
wiley +1 more source
Absolute quantification of viral proteins from pseudotyped VSV-GP using UPLC-MRM. [PDF]
Basu R+8 more
europepmc +1 more source
Safety Evaluation of Repeated Application of Polymeric Microarray Patches in Miniature Pigs
This study demonstrates the safety of repeated application of three types of microarray patches (MAPs), hydrogelforming, dissolving, and implantable, over four weeks in miniature pigs. No adverse skin or systemic effects were observed, supporting the clinical potential of MAPs as safe and effective drug delivery platforms.
Qonita Kurnia Anjani+4 more
wiley +1 more source